These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36260562)

  • 21. The involvement of the MAPK pathway in pilocytic astrocytomas.
    Salles D; Santino SF; Ribeiro DA; Malinverni ACM; Stávale JN
    Pathol Res Pract; 2022 Apr; 232():153821. PubMed ID: 35231859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas.
    Becker AP; Scapulatempo-Neto C; Carloni AC; Paulino A; Sheren J; Aisner DL; Musselwhite E; Clara C; Machado HR; Oliveira RS; Neder L; Varella-Garcia M; Reis RM
    J Neuropathol Exp Neurol; 2015 Jul; 74(7):743-54. PubMed ID: 26083571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas.
    Jacob K; Quang-Khuong DA; Jones DT; Witt H; Lambert S; Albrecht S; Witt O; Vezina C; Shirinian M; Faury D; Garami M; Hauser P; Klekner A; Bognar L; Farmer JP; Montes JL; Atkinson J; Hawkins C; Korshunov A; Collins VP; Pfister SM; Tabori U; Jabado N
    Clin Cancer Res; 2011 Jul; 17(14):4650-60. PubMed ID: 21610151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pilomyxoid Astrocytoma (PMA) Shows Significant Differences in Gene Expression vs. Pilocytic Astrocytoma (PA) and Variable Tendency Toward Maturation to PA.
    Kleinschmidt-DeMasters BK; Donson AM; Vogel H; Foreman NK
    Brain Pathol; 2015 Jul; 25(4):429-40. PubMed ID: 25521223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PIK3CA mutations in advanced cancers: characteristics and outcomes.
    Janku F; Wheler JJ; Naing A; Stepanek VM; Falchook GS; Fu S; Garrido-Laguna I; Tsimberidou AM; Piha-Paul SA; Moulder SL; Lee JJ; Luthra R; Hong DS; Kurzrock R
    Oncotarget; 2012 Dec; 3(12):1566-75. PubMed ID: 23248156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of Multi-kinase Allosteric Inhibitors of Oncogenic Targets EGFR1, PI3K, and BRAF Kinase.
    Kakarala KK; Jamil K
    Curr Comput Aided Drug Des; 2022; 18(7):506-518. PubMed ID: 36321226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenotypic variations in NF1-associated low grade astrocytomas: possible role for increased mTOR activation in a subset.
    Jentoft M; Giannini C; Cen L; Scheithauer BW; Hoesley B; Sarkaria JN; Abell-Aleff PC; Rodriguez EF; Li Y; Rodriguez FJ
    Int J Clin Exp Pathol; 2010 Dec; 4(1):43-57. PubMed ID: 21228927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model.
    Raabe EH; Lim KS; Kim JM; Meeker A; Mao XG; Nikkhah G; Maciaczyk J; Kahlert U; Jain D; Bar E; Cohen KJ; Eberhart CG
    Clin Cancer Res; 2011 Jun; 17(11):3590-9. PubMed ID: 21636552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ATRX protein loss and deregulation of PI3K/AKT pathway is frequent in pilocytic astrocytoma with anaplastic features.
    Olar A; Tran D; Mehta VP; Reinhardt A; Manekia JH; Garnovskaya M; Ellezam B; Luthra R; Sulman EP; Mohila CA; Campbell GA; Powell SZ; Fuller GN; Aldape KD; Adesina AM
    Clin Neuropathol; 2019; 38(2):59-73. PubMed ID: 30499772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical relevance of BRAF status in glial and glioneuronal tumors: A systematic review.
    Sugiura Y; Nagaishi M
    J Clin Neurosci; 2019 Aug; 66():196-201. PubMed ID: 31147232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma.
    Bar EE; Lin A; Tihan T; Burger PC; Eberhart CG
    J Neuropathol Exp Neurol; 2008 Sep; 67(9):878-87. PubMed ID: 18716556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adult pilocytic astrocytoma in the molecular era: a comprehensive review.
    Gregory TA; Chumbley LB; Henson JW; Theeler BJ
    CNS Oncol; 2021 Mar; 10(1):CNS68. PubMed ID: 33448230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alterations in BRAF gene, and enhanced mTOR and MAPK signaling in dysembryoplastic neuroepithelial tumors (DNTs).
    Kakkar A; Majumdar A; Kumar A; Tripathi M; Pathak P; Sharma MC; Suri V; Tandon V; Chandra SP; Sarkar C
    Epilepsy Res; 2016 Nov; 127():141-151. PubMed ID: 27599148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MAPK pathway activation through BRAF gene fusion in pilocytic astrocytomas; a novel oncogenic fusion gene with diagnostic, prognostic, and therapeutic potential.
    Jeuken JW; Wesseling P
    J Pathol; 2010 Dec; 222(4):324-8. PubMed ID: 20976706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome analysis of childhood pilocytic astrocytomas: a retrospective study of 148 cases at a single institution.
    Colin C; Padovani L; Chappé C; Mercurio S; Scavarda D; Loundou A; Frassineti F; André N; Bouvier C; Korshunov A; Lena G; Figarella-Branger D
    Neuropathol Appl Neurobiol; 2013 Oct; 39(6):693-705. PubMed ID: 23278243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
    Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
    Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.
    Jones DT; Hutter B; Jäger N; Korshunov A; Kool M; Warnatz HJ; Zichner T; Lambert SR; Ryzhova M; Quang DA; Fontebasso AM; Stütz AM; Hutter S; Zuckermann M; Sturm D; Gronych J; Lasitschka B; Schmidt S; Seker-Cin H; Witt H; Sultan M; Ralser M; Northcott PA; Hovestadt V; Bender S; Pfaff E; Stark S; Faury D; Schwartzentruber J; Majewski J; Weber UD; Zapatka M; Raeder B; Schlesner M; Worth CL; Bartholomae CC; von Kalle C; Imbusch CD; Radomski S; Lawerenz C; van Sluis P; Koster J; Volckmann R; Versteeg R; Lehrach H; Monoranu C; Winkler B; Unterberg A; Herold-Mende C; Milde T; Kulozik AE; Ebinger M; Schuhmann MU; Cho YJ; Pomeroy SL; von Deimling A; Witt O; Taylor MD; Wolf S; Karajannis MA; Eberhart CG; Scheurlen W; Hasselblatt M; Ligon KL; Kieran MW; Korbel JO; Yaspo ML; Brors B; Felsberg J; Reifenberger G; Collins VP; Jabado N; Eils R; Lichter P; Pfister SM;
    Nat Genet; 2013 Aug; 45(8):927-32. PubMed ID: 23817572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new NFIA:RAF1 fusion activating the MAPK pathway in pilocytic astrocytoma.
    Yde CW; Sehested A; Mateu-Regué À; Østrup O; Scheie D; Nysom K; Nielsen FC; Rossing M
    Cancer Genet; 2016 Oct; 209(10):440-444. PubMed ID: 27810072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
    J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas.
    Forshew T; Tatevossian RG; Lawson AR; Ma J; Neale G; Ogunkolade BW; Jones TA; Aarum J; Dalton J; Bailey S; Chaplin T; Carter RL; Gajjar A; Broniscer A; Young BD; Ellison DW; Sheer D
    J Pathol; 2009 Jun; 218(2):172-81. PubMed ID: 19373855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.